-+ 0.00%
-+ 0.00%
-+ 0.00%

Medincell FY26 operating loss widens to €20.8 million

PUBT·06/16/2026 15:45:25
Listen to the news
Medincell FY26 operating loss widens to €20.8 million
  • Medincell posted FY 2025-26 revenue of €24.3 million, including €9.3 million in UZEDY royalties as the product ramp-up continued.
  • Operating loss widened to €20.8 million as operating expenses rose 17% year over year to €45 million to support pipeline expansion.
  • Liquidity stood at €84.8 million, boosted by a €48.2 million fund raising in March 2026.
  • Olanzapine LAI advanced into regulatory review, ahead of Teva’s expected U.S. launch in Q4 2026.
  • CEO Christophe Douat said the group is moving into a “Shift to Growth” phase, building a pipeline aimed at milestone and recurring royalty revenues.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202606161145BIZWIRE_USPR_____20260616_BW763165) on June 16, 2026, and is solely responsible for the information contained therein.